| Entry |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Haloperidol (JP18/USP/INN); Haldol (TN) | ||||||||||||
| Product | |||||||||||||
| Generic | HALOPERIDOL (A-S Medication Solutions), HALOPERIDOL (A-S Medication Solutions), HALOPERIDOL (A-S Medication Solutions), HALOPERIDOL (A-S Medication Solutions), HALOPERIDOL (ATLANTIC BIOLOGICALS CORP.), HALOPERIDOL (American Health Packaging), HALOPERIDOL (American Health Packaging), HALOPERIDOL (Amici Pharmaceuticals), HALOPERIDOL (AvPAK), HALOPERIDOL (AvPAK), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Burel Pharmaceuticals), HALOPERIDOL (Burel Pharmaceuticals), HALOPERIDOL (Burel Pharmaceuticals), HALOPERIDOL (Cadila Healthcare Limited), HALOPERIDOL (Cardinal Health), HALOPERIDOL (Cardinal Health), HALOPERIDOL (DIRECT RX), HALOPERIDOL (Innogenix), HALOPERIDOL (Major Pharmaceuticals), HALOPERIDOL (Major Pharmaceuticals), HALOPERIDOL (Major Pharmaceuticals), HALOPERIDOL (Method Pharmaceuticals), HALOPERIDOL (Mylan Institutional), HALOPERIDOL (Mylan Pharmaceuticals), HALOPERIDOL (NCS HealthCare of KY), HALOPERIDOL (Proficient Rx LP), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (Upsher-Smith Laboratories), HALOPERIDOL (Zydus Pharmaceuticals (USA)) | ||||||||||||
| Formula | C21H23ClFNO2 | ||||||||||||
| Exact mass | 375.1401 | ||||||||||||
| Mol weight | 375.8642 | ||||||||||||
| Structure |  | ||||||||||||
| Simcomp | |||||||||||||
| Class | Neuropsychiatric agent DG01478 Dopamine antagonist DG01474 Dopamine D2-receptor antagonist DG03200 Antipsychotic agent DG01940 Butyrophenone derivative Metabolizing enzyme substrate DG01644 CYP2D6 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||||||||
| Remark |
| ||||||||||||
| Efficacy | Antipsychotic, Antidyskinetic, Neuroleptic, Dopamine D2 receptor antagonist | ||||||||||||
| Disease | Tourette’s disorder [DS:H00862] | ||||||||||||
| Comment | Butyrophenone derivative | ||||||||||||
| Target | DRD2 [HSA:1813] [KO:K04145] | ||||||||||||
| Pathway |
| ||||||||||||
| Metabolism | Enzyme: CYP2D6 [HSA:1565], CYP3A4 [HSA:1576] | ||||||||||||
| Interaction | |||||||||||||
| Structure map |
| ||||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N05 PSYCHOLEPTICS N05A ANTIPSYCHOTICS N05AD Butyrophenone derivatives N05AD01 Haloperidol D00136 Haloperidol (JP18/USP/INN) <JP/US> USP drug classification [BR:br08302] Antipsychotics 1st Generation/Typical Haloperidol D00136 Haloperidol (JP18/USP/INN) Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 117 Psychotropics 1179 Others D00136 Haloperidol (JP18/USP/INN) Drug groups [BR:br08330] Neuropsychiatric agent DG01478 Dopamine antagonist DG01474 Dopamine D2-receptor antagonist DG00885 Haloperidol D00136 Haloperidol DG03200 Antipsychotic agent DG01940 Butyrophenone derivative DG00885 Haloperidol D00136 Haloperidol Metabolizing enzyme substrate DG01644 CYP2D6 substrate DG00885 Haloperidol D00136 Haloperidol DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG00885 Haloperidol D00136 Haloperidol Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Dopamine DRD2 D00136 Haloperidol (JP18/USP/INN) <JP/US> Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D00136 Haloperidol D00136 Haloperidol tablets D00136 Haloperidol fine granules D00136 Haloperidol injection Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D00136 Prodrugs [br08324.html] D00136 Drug groups [BR:br08330] Neuropsychiatric agent DG01478 Dopamine antagonist DG01474 Dopamine D2-receptor antagonist DG00885 Haloperidol DG03200 Antipsychotic agent DG01940 Butyrophenone derivative DG00885 Haloperidol Metabolizing enzyme substrate DG01644 CYP2D6 substrate DG00885 Haloperidol DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG00885 Haloperidol Prodrugs [br08324.html] DG00885 | ||||||||||||
| Other DBs |
| ||||||||||||
| KCF data | ATOM 26 1 C1b C 19.7303 -17.5616 2 C1b C 20.9898 -16.8619 3 C1b C 22.2494 -17.5616 4 N1y N 23.4389 -16.8619 5 C1x C 23.4389 -15.4624 6 C1x C 24.6285 -17.5616 7 C1x C 24.6285 -14.7626 8 C1x C 25.8181 -16.8619 9 C1z C 25.8181 -15.4624 10 C8y C 27.0076 -14.7626 11 C8x C 27.0076 -13.4331 12 C8x C 28.2672 -15.4624 13 C8x C 28.2672 -12.7334 14 C8x C 29.4567 -14.7626 15 C8y C 29.4567 -13.4331 16 X Cl 30.6463 -12.7334 17 C5a C 18.5407 -16.8619 18 C8y C 17.3512 -17.5616 19 O5a O 18.5407 -15.3924 20 C8x C 17.3512 -18.9611 21 C8x C 16.0916 -19.6608 22 C8y C 14.8321 -18.9611 23 C8x C 14.8321 -17.5616 24 C8x C 16.0916 -16.8619 25 X F 13.6425 -19.6608 26 O1a O 27.0305 -16.1624 BOND 28 1 9 10 1 2 10 11 1 3 10 12 2 4 11 13 2 5 12 14 1 6 13 15 1 7 15 16 1 8 8 9 1 9 14 15 2 10 1 17 1 11 1 2 1 12 17 18 1 13 2 3 1 14 17 19 2 15 3 4 1 16 4 5 1 17 4 6 1 18 5 7 1 19 6 8 1 20 18 20 1 21 20 21 2 22 21 22 1 23 22 23 2 24 23 24 1 25 24 18 2 26 7 9 1 27 22 25 1 28 9 26 1 |